ArticleRheumatology and therapy2026
Filgotinib in Moderate to Severe Rheumatoid Arthritis in a Real-World Setting: Up to 6-Month Effectiveness, Patient-Reported Outcomes, and Persistence, and up to 24-Month Safety from More than 1400 Patients in the FILOSOPHY and PARROTFISH Studies.
Article in Rheumatology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Prospective, Non-interventional Study of the Effectiveness, Safety, and Health Related Outcomes in Patients With Moderate to Severe Active Rheumatoid Arthritis Receiving Filgotinib
A Prospective, Non-interventional Study in Patients With Moderate to Severe Active Rheumatoid Arthritis in France Receiving Filgotinib for 2 Years
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionFILOSOPHY (NCT04871919) and PARROTFISH (NCT05323591) are ongoing, prospective observational European phase 4 studies of filgotinib in patients with rheumatoid arthritis (RA) in a real-world setting. We report the study design, baseline characteristics, and interim results for disease activity measures, patient-reported outcomes (PROs), and treatment persistence up to 6 months and safety up to 24 months.
methodsEligible patients had moderate to severe RA and were prescribed filgotinib for the first time in daily practice. In this interim analysis, measures include the proportion of patients achieving low disease activity (LDA), according to Disease Activity Score for 28 joint count using C-reactive protein (DAS28-CRP) or Clinical Disease Activity Index (CDAI), and the proportion achieving a clinically meaningful change from baseline in visual analog scale (VAS) pain (≥ 10 mm reduction) and in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue score (≥ 4.0 increase). Treatment persistence was estimated using the Kaplan-Meier method. Treatment-emergent adverse events (TEAEs) are reported.
resultsFrom May 2021 to April 2025, 1431 patients initiated filgotinib treatment; 93.0% had completed at least 6 months of follow-up (median follow-up 706 days). Improvements in DAS28-CRP and CDAI occurred from month 1. By month 6, DAS28-CRP ≤ 2.6 was reported for 58.1% (494/850) of patients and CDAI remission for 25.7% (221/859). The proportion with LDA was 71.4% (607/850) based on DAS28-CRP and 69.8% (600/859) based on CDAI. The proportion with a clinically meaningful change from baseline in VAS pain and FACIT-Fatigue score was 44.1% (178/404) and 43.8% (176/402), respectively, at week 1, increasing to 69.6% (227/326) and 62.5% (202/323), respectively, at month 6. Treatment persistence (95% CI) at month 6 was 84.0% (82.0, 85.8). Up to month 24, the exposure-adjusted incidence rates per 100 patient-years of exposure (95% CI) of any TEAEs and serious TEAEs were 89.8 (84.1, 95.8) and 9.4 (8.0, 10.8), respectively.
conclusionInterim data from FILOSOPHY/PARROTFISH showed improvement of disease activity from month 1 and PROs from week 1, high treatment persistence at 6 months, and no new safety signals. These findings continue to support the safety and effectiveness of filgotinib in daily clinical practice.
trial registrationClinicalTrials.gov: NCT04871919 (2021-04-29), NCT05323591(2022-04-05).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.